KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$22.5 million.

  • Amneal Pharmaceuticals' Cash from Investing Activities fell 845.89% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.9 million, marking a year-over-year decrease of 539.11%. This contributed to the annual value of -$63.0 million for FY2024, which is 895.08% up from last year.
  • Amneal Pharmaceuticals' Cash from Investing Activities amounted to -$22.5 million in Q3 2025, which was down 845.89% from -$26.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$6.5 million during Q2 2024, with a 5-year trough of -$97.4 million in Q1 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Cash from Investing Activities value was -$17.8 million (recorded in 2025), while the average stood at -$29.9 million.
  • Over the last 5 years, Amneal Pharmaceuticals' Cash from Investing Activities had its largest YoY gain of 9515.61% in 2021, and its largest YoY loss of 82849.78% in 2021.
  • Amneal Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$87.0 million in 2021, then skyrocketed by 86.82% to -$11.5 million in 2022, then plummeted by 176.4% to -$31.7 million in 2023, then soared by 49.33% to -$16.1 million in 2024, then tumbled by 39.88% to -$22.5 million in 2025.
  • Its Cash from Investing Activities stands at -$22.5 million for Q3 2025, versus -$26.5 million for Q2 2025 and -$17.8 million for Q1 2025.